Browse > Article

MethA Fibrosarcoma Cells Expressing Membrane-Bound Forms of IL-2 Enhance Antitumor Immunity  

Sonn, Chung-Hee (Department of Biochemistry, College of Natural Sciences, Chungnam National University)
Yoon, Hee-Ryung (Department of Biochemistry, College of Natural Sciences, Chungnam National University)
Seong, In-Ock (Department of Biochemistry, College of Natural Sciences, Chungnam National University)
Chang, Mi-Ra (Department of Biochemistry, College of Natural Sciences, Chungnam National University)
Kim, Yong-Chan (Department of Biochemistry, College of Natural Sciences, Chungnam National University)
Kang, Han-Chul (Transgene Expression Team, National Institute of Agricultural Biotechnology, Rural Development Administration)
Suh, Seok-Cheol (Transgene Expression Team, National Institute of Agricultural Biotechnology, Rural Development Administration)
Kim, Young-Sang (Department of Biochemistry, College of Natural Sciences, Chungnam National University)
Publication Information
Journal of Microbiology and Biotechnology / v.16, no.12, 2006 , pp. 1919-1927 More about this Journal
Abstract
Tumor cells genetically engineered to secrete cytokines are effective in tumor therapy, but various unexpected side effects are observed, which may result from the bulk activation of various bystander cells. In this study, we tested tumor vaccines expressing various membrane-bound forms of IL-2 (mbIL-2) on MethA fibrosarcoma cells to focus antitumor immune responses to CTL. Chimeric forms of IL-2 with whole CD4, deletion forms of CD4, and TNF were expressed on the tumor cell surface, respectively. Tumor clones expressing mbIL-2 or secretory form of IL-2 were able to support the cell growth of CTLL-2, an IL-2-dependent T cell line, and the proliferation of spleen cells from 2C TCR transgenic mice that are responsive to the $p2Ca/L^d$ MHC class I complex. Expression of mbIL-2 on tumor cells reduced the tumorigenicity of tumor cells, and the mice that once rejected the live IL-2/TNF tumor clone acquired systemic immunity against wild-type MethA cells. The IL-2/TNF clone was inferior to other clones in tumor formation, and superior in the stimulation of the CD8+ T cell population in vitro. These results suggest that the IL-2/TNF clone is the best tumor vaccine, and may stimulate CD8+ T cells by direct priming. Expression of IL-2/TNF on tumor cells may serve as an effective gene therapy method to ameliorate the side effects encountered in the recombinant cytokine therapy and the conventional cytokine gene therapy using the secretory form of IL-2.
Keywords
IL-2; membrane-bound form; antitumor immunity; tumor vaccine; direct priming; CTL;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
Times Cited By Web Of Science : 7  (Related Records In Web of Science)
연도 인용수 순위
1 Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S. A. Rosenberg. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17: 2105- 2116   DOI
2 Baskar, S., N. Nabavi, L. H. Glimcher, and S. Ostrand-Rosenberg. 1993. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity. J. Immunother. 14: 209- 215   DOI
3 el-Shami, K. M., E. Tzehoval, E. Vadai, M. Feldman, and L. Eisenbach. 1999. Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines. J. Interferon Cytokine Res. 19: 1391-1401   DOI   ScienceOn
4 Gansbacher, B., K. Zier, B. Daniels, K. Cronin, R. Bannerji, and E. Gilboa. 1990. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172: 1217-1224   DOI
5 Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrowderived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965   DOI
6 Kammula, U. S., D. E. White, and S. A. Rosenberg. 1998. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83: 797-805   DOI   ScienceOn
7 Kim, H. Y., J. O. Yang, and G. O. Ji. 2005. Effect of bifidobacteria on production of allergy-related cytokines from mouse spleen cells. J. Microbiol. Biotechnol. 15: 265- 268   과학기술학회마을   DOI   ScienceOn
8 Lu, X., N. L. Kallinteris, J. Li, S. Wu, Y. Li, Z. Jiang, G. G. Hillman, J. V. Gulfo, R. E. Humphreys, and M. Xu. 2003. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol. Immunother. 52: 592-598   DOI   ScienceOn
9 Marr, R. A., C. L. Addison, D. Snider, W. J. Muller, J. Gauldie, and F. L. Graham. 1997. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. Gene Ther. 4: 1181-1188   DOI
10 Rivoltini, L., C. Gambacorti-Passerini, M. Squadrelli-Saraceno, M. I. Grosso, G. Cantu, R. Molinari, A. Orazi, and G. Parmiani. 1990. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res. 50: 5551-5557
11 Tepper, R. I. and J. J. Mule. 1994. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5: 153-164   DOI   ScienceOn
12 Tjuvajev, J., B. Gansbacher, R. Desai, B. Beattie, M. Kaplitt, C. Matei, J. Koutcher, E. Gilboa, and R. Blasberg. 1995. RG- 2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 55: 1902-1910
13 Townsend, S. E. and J. P. Allison. 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368-370   DOI
14 Wolkers, M. C., G. Stoetter, F. A. Vyth-Dreese, and T. N. Schumacher. 2001. Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses. J. Immunol. 167: 3577-3584   DOI
15 Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403   DOI   ScienceOn
16 Gabrilovich, D. I., I. F. Ciernik, and D. P. Carbone. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 170: 101-110   DOI   ScienceOn
17 Kriegler, M., C. Perez, K. DeFay, I. Albert, and S. D. Lu. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53: 45-53   DOI   ScienceOn
18 Cimino, A. M., P. Palaniswami, A. C. Kim, and P. Selvaraj. 2004. Cancer vaccine development: Protein transfer of membrane-anchored cytokines and immunostimulatory molecules. Immunol. Res. 29: 231-240   DOI   ScienceOn
19 Lotze, M. T., Y. L. Matory, A. A. Rayner, S. E. Ettinghausen, J. T. Vetto, C. A. Seipp, and S. A. Rosenberg. 1986. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 2764-2772   DOI   ScienceOn
20 Kundig, T. M., M. F. Bachmann, C. DiPaolo, J. J. Simard, M. Battegay, H. Lother, A. Gessner, K. Kuhlcke, P. S. Ohashi, H. Hengartner, et al. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268: 1343-1347   DOI
21 Leonard, J. P., M. L. Sherman, G. L. Fisher, L. J. Buchanan, G. Larsen, M. B. Atkins, J. A. Sosman, J. P. Dutcher, N. J. Vogelzang, and J. L. Ryan. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548
22 Chen, B., T. M. Timiryasova, D. S. Gridley, M. L. Andres, R. Dutta-Roy, and I. Fodor. 2001. Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy. Cytokine 15: 305-314   DOI   ScienceOn
23 Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, and D. Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335: 271-274   DOI   ScienceOn
24 Wang, Y. C., L. Zhu, R. McHugh, K. W. Sell, and P. Selvaraj. 1995. Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice. Eur. J. Immunol. 25: 1163-1167   DOI   ScienceOn
25 Vesosky, B. and A. A. Hurwitz. 2003. Modulation of costimulation to enhance tumor immunity. Cancer Immunol. Immunother. 52: 663-669   DOI
26 Luo, L., A. I. Chapoval, D. B. Flies, G. Zhu, F. Hirano, S. Wang, J. S. Lau, H. Dong, K. Tamada, A. S. Flies, Y. Liu, and L. Chen. 2004. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J. Immunol. 173: 5445-5450   DOI
27 Colombo, M. P., A. Modesti, G. Parmiani, and G. Forni. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte crosstalk. Cancer Res. 52: 4853-4857
28 Salvadori, S., B. Gansbacher, A. M. Pizzimenti, and K. S. Zier. 1994. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2- secreting tumors. J. Immunol. 153: 5176-5182
29 Chang, M. R., W. H. Lee, J. W. Choi, S. O. Park, S. G. Paik, and Y. S. Kim. 2005. Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2. Exp. Mol. Med. 37: 240-249   DOI   ScienceOn
30 Udaka, K., T. J. Tsomides, and H. N. Eisen. 1992. A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell 69: 989-998   DOI   ScienceOn
31 Jackaman, C., C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. Robinson, and D. J. Nelson. 2003. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumorassociated vasculature: A novel mechanism for IL-2. J. Immunol. 171: 5051-5063   DOI
32 Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumorbearing mice. Science 258: 1795-1798   DOI
33 Soo, H. W., K. A. Lundeen, J. R. Kohrumel, N. L. Pham, S. W. Brostoff, R. M. Bartholomew, and D. J. Carlo. 1999. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. J. Immunol. 162: 7343-7349
34 Yei, S., R. M. Bartholomew, P. Pezzoli, A. Gutierrez, E. Gouveia, D. Bassett, W. Soo Hoo, and D. J. Carlo. 2002. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: Generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Gene Ther. 9: 1302-1311   DOI   ScienceOn
35 Bai, X. F., J. Bender, J. Liu, H. Zhang, Y. Wang, O. Li, P. Du, P. Zheng, and Y. Liu. 2001. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J. Immunol. 167: 3936-3943   DOI
36 Browning, J. L., A. Ngam-ek, P. Lawton, J. DeMarinis, R. Tizard, E. P. Chow, C. Hession, B. O'Brine-Greco, S. F. Foley, and C. F. Ware. 1993. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72: 847-856   DOI   ScienceOn
37 Hillman, G. G., P. Slos, Y. Wang, J. L. Wright, A. Layer, M. De Meyer, M. Yudelev, M. Che, and J. D. Forman. 2004. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Cancer Gene Ther. 11: 61-72   DOI   ScienceOn
38 Zier, K., B. Gansbacher, and S. Salvadori. 1996. Preventing abnormalities in signal transduction of T cells in cancer: The promise of cytokine gene therapy. Immunol. Today 17: 39- 45   DOI   ScienceOn
39 Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543
40 Kim, E. J., D. J. Kim, H. Y. Hwang, J. S. Yoon, Y. Yoon, and K. H. Baek. 2004. High-level expression of recombinant human interleukin-2 in Chinese hamster ovary cells using the expression system containing transcription terminator. J. Microbiol. Biotechnol. 14: 810-815
41 Assenmacher, M., A. Scheffold, J. Schmitz, J. A. Segura Checa, S. Miltenyi, and A. Radbruch. 1996. Specific expression of surface interferon-gamma on interferon-gamma producing T cells from mouse and man. Eur. J. Immunol. 26: 263-267   DOI   ScienceOn
42 Chen, K., S. Braun, S. Lyman, Y. Fan, C. M. Traycoff, E. A. Wiebke, J. Gaddy, G. Sledge, H. E. Broxmeyer, and K. Cornetta. 1997. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57: 3511-3516
43 Kim, Y. S., C. H. Sonn, S. G. Paik, and A. L. Bothwell. 2000. Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity. Gene Ther. 7: 837-843   DOI
44 Blankenstein, T., D. A. Rowley, and H. Schreiber. 1991. Cytokines and cancer: Experimental systems. Curr. Opin. Immunol. 3: 694-698   DOI   ScienceOn
45 Nanni, P., G. Forni, and P. L. Lollini. 1999. Cytokine gene therapy: Hopes and pitfalls. Ann. Oncol. 10: 261-266
46 Yang, J. C., L. Haworth, R. M. Sherry, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, S. M. Steinberg, H. X. Chen, and S. A. Rosenberg. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349: 427-434   DOI   ScienceOn
47 Kurt-Jones, E. A., W. Fiers, and J. S. Pober. 1987. Membrane interleukin 1 induction on human endothelial cells and dermal fibroblasts. J. Immunol. 139: 2317-2324
48 Dranoff, G. and R. C. Mulligan. 1995. Gene transfer as cancer therapy. Adv. Immunol. 58: 417-454   DOI
49 Lollini, P. L. and G. Forni. 2003. Cancer immunoprevention: Tracking down persistent tumor antigens. Trends Immunol. 24: 62-66   DOI   ScienceOn
50 Nizard, P., D. A. Gross, A. Babon, A. Chenal, B. Beaumelle, K. Kosmatopoulos, and D. Gillet. 2003. Anchoring cytokines MEMBRANE-BOUND FORMS OF IL-2 FOR TUMOR THERAPY 1927 to tumor cells for the preparation of anticancer vaccines without gene transfection in mice. J. Immunother. 26: 63- 71   DOI